Cost Analysis of Biosimilar vs Reference Rituximab for Treating CLL and Other Diseases
Dec 19, 2023
Rituximab-abbs may have more economic benefits compared to rituximab in patients with non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis, according to a study presented at the virtual 2021 ASCO Annual Meeting. These findings were presented by Elizabeth James, MD, Aventine Consulting, LLC, Marblehead, MA, lead author of the study. Rituximab-abbs, the first rituximab biosimilar approved in the US, with the expectation of reducing drug acquisition costs, is an important antibody and immune-oncology agent for the treatment of B-cell malignancies, follicular lymphoma, CLL, and NHL, while also indicated for patients with rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.
Radiation Oncologists Met With Congressional Leaders to Reverse CMS Cuts and Provide Equal Access to Care
Radiation oncologists met with Congress to urge leaders to consider how the Medicare and Medicaid Services (CMS) proposal to make significant cuts to radiation oncology facilities could be detrimental to the survival of patients with Read more…
FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication
The FDA granted approval to the supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as neoadjuvant therapy for patients with high-risk early-stage triple-negative breast cancer (TNBC) when given in combination with chemotherapy followed by single-agent Read more…
Recommended TVUS Screening Thresholds May Miss Endometrial Cancer in Black Women
Adherence to current clinical guidelines for the evaluation of postmenopausal bleeding may result in systematic underdiagnosis of endometrial cancer (EC) in Black women, according to a study published online July 15 in JAMA Oncology. Kemi M. Read more…